Cannabis in the Arm: What Can we Learn from Intravenous Cannabinoid Studies?

Research output: Contribution to journalLiterature reviewpeer-review

10 Citations (Scopus)


Cannabis is widely used recreationally and for symptomatic relief in a number of ailments. However, cannabis has been implicated as a risk factor for the development of psychotic illness. For forty years researchers have utilised intravenous preparations of Delta(9)-THC, as well as several other phytocannabinoids, in a laboratory setting. The intravenous route has the most reliable pharmacokinetics, reducing inter-individual variation in bioavailability and is well suited for the delivery of synthetic compounds containing a sole pharmacological moiety. Given the association between cannabinoids and psychotic illness, there has been a resurgence of interest in experimental studies of cannabinoids in humans, and the intravenous route has been employed. Here in a critical review, we appraise the major findings from recent intravenous cannabinoid studies in humans and trace the historical roots of this work back to the 1970's.

Original languageEnglish
Pages (from-to)4906-4914
Number of pages9
JournalCurrent Pharmaceutical Design
Issue number32
Publication statusPublished - Nov 2012


Dive into the research topics of 'Cannabis in the Arm: What Can we Learn from Intravenous Cannabinoid Studies?'. Together they form a unique fingerprint.

Cite this